Yes, this PSA increase is significant and warrants further evaluation.
A PSA rise from 0.7 to 1.95 ng/mL over 3 years in an 80-year-old man represents a PSA velocity of approximately 0.42 ng/mL/year, which meets established thresholds for concern and should prompt urologic referral or repeat PSA testing with consideration for prostate biopsy.
Understanding the PSA Velocity
The key issue here is not just the absolute PSA value (which remains below the traditional 4.0 ng/mL threshold), but rather the rate of change:
- Total increase: 1.25 ng/mL over 3 years
- Annual velocity: ~0.42 ng/mL/year
Multiple approaches from published guidelines 1 indicate this velocity is concerning:
- The Endocrine Society recommends biopsy for PSA increases >0.75 ng/mL/year over 2 years
- Bhasin et al. recommend biopsy for increases >0.4 ng/mL/year (your patient exceeds this)
- Observational studies suggest biopsy for increases of 1.5 ng/mL within 2 years (your patient has 1.25 ng/mL over 3 years, approaching this threshold)
Age-Specific Context
At 80 years old, several factors modify the interpretation:
Arguments for significance:
- While the absolute PSA of 1.95 ng/mL is within age-adjusted reference ranges (upper limit ~7.92 ng/mL for men ≥70 years 2), the velocity is what matters most
- The PSA level is above the median for this age group (median ~2.1-2.8 ng/mL for men in their 70s-80s 3, 4)
- Recent evidence 5 shows men with PSA <2.0 ng/mL and free/total PSA ≥0.25 have very low long-term prostate cancer death risk (1.5%), but this assumes stable PSA, not rising
Arguments for caution:
- Life expectancy considerations are critical at age 80
- Screening guidelines 6 recommend caution above age 75, suggesting testing "only in very healthy men with little or no comorbidity"
- The absolute PSA remains <4.0 ng/mL
Recommended Action Algorithm
Step 1: Repeat PSA in 3-6 months 1
- Confirm the rising trend
- Consider adding free/total PSA ratio if available
Step 2: If PSA continues to rise:
- Any further increase: Strong consideration for urologic referral
- Total yearly increase ≥1.0 ng/mL: Definite urologic referral for biopsy consideration 1
- Increase of 0.7-0.9 ng/mL in one year: Repeat PSA in 3-6 months and refer if any further increase 1
Step 3: Perform digital rectal examination (DRE)
- Any abnormality on DRE warrants immediate urologic referral regardless of PSA 1
Step 4: Consider patient factors:
- Life expectancy >10 years AND good functional status: Proceed with full evaluation
- Significant comorbidities or limited life expectancy (<7-10 years): Consider watchful waiting, as detection may not improve mortality or quality of life
Critical Caveats
- This is NOT about testosterone replacement: The guidelines cited [1-1-1] primarily address PSA monitoring during testosterone therapy, but the velocity thresholds they establish are applicable to general PSA surveillance
- Benign causes exist: Prostatitis, benign prostatic hyperplasia, or recent instrumentation can elevate PSA
- Overdiagnosis risk: At age 80, detecting indolent prostate cancer that would never cause symptoms is a real concern
- Shared decision-making is essential: Discuss the patient's values, life expectancy, comorbidities, and willingness to undergo biopsy and potential treatment
Bottom Line
The PSA velocity of 0.42 ng/mL/year is significant by established criteria and warrants repeat testing in 3-6 months. If the rise continues, urologic evaluation should be pursued in an otherwise healthy 80-year-old with reasonable life expectancy. However, if the patient has significant comorbidities or limited functional status, observation may be more appropriate than aggressive investigation.